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Abstract
Introduction: Results on the evolution of the clinical status of patients undergoing cardiac resynchronization
therapy with a defibrillator after automatic optimization of their cardiac resynchronization therapy are scarce. We
observed a rapid and important change in the clinical status of our non-responding patient following activation of
a sensor capable of weekly atrioventricular and interventricular delays' optimization.
Case presentation: A 78-year-old Caucasian man presented with dilated cardiomyopathy, left bundle branch block,
a left ventricular ejection fraction of 35 %, New York Heart Association class III/IV heart failure, and paroxysmal atrial
fibrillation. Our patient was implanted with a cardiac resynchronization device with a defibrillator and the SonRtip
atrial lead. Right ventricular and left ventricular leads were also implanted. Because of the recurrence of atrial
fibrillation, the automatic optimization was set off at discharge. Consequently, the device did not optimize
atrioventricular and interventricular delays (programming at discharge: 125 ms for the atrioventricular delay and 0
ms for the interventriculardelay). Our patient was treated with an anti-arrhythmic drug. Five months after
implantation, his clinical status remained impaired (left ventricular ejection fraction = 30 %). The SonR signal
amplitude had also decreased from 0.52 g to 0.29 g. Nevertheless, because our patient was no longer presenting
with atrial fibrillation, the anti-arrhythmic treatment was stopped and the SonR optimization system was activated.
After 2 months of automatic cardiac resynchronization therapy with defibrillator optimization, our patient’s clinical
status had significantly improved (left ventricular ejection fraction = 60 %, New York Heart Association class II) and
the SonR signal amplitude had doubled shortly after the first weekly automatic optimization.
Conclusion: In this non-responding patient, device-based automatic cardiac resynchronization therapy optimization
was shown to significantly improve his clinical status.
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Introduction
Cardiac resynchronization therapy (CRT) is an established
therapy for patients with heart failure symptoms, left ven-
tricular (LV) systolic dysfunction, and a wide QRS, on top
of optimal medical therapy [1, 2]. However, the magnitude
of clinical and hemodynamic benefit of CRT among recipi-
ents varies and non-responders can account for up to 30
% of treated patients [1]. The non-response can be partly
caused by inappropriate settings of atrioventricular (AV)
and interventricular (VV) delays leading to persistent AV,
VV, and intraventricular dysynchrony. Several methods
have been developed to optimize AV and VV delays, in-
cluding device-based algorithms allowing automatic
optimization of delays [3]. Encapsulated in the SonRtip
atrial lead (Sorin CRM SAS, Clamart, France), the
hemodynamic SonR sensor automatically optimizes AV
and VV delays weekly in patients with heart failure in
sinus rhythm, at rest, and during exercise [4].
The SonR sensor was clinically evaluated in the CLEAR
multicenter, single-blind, randomized (1:1) pilot study (n
= 199) using the SonR system integrated in a CRT device
with a pacemaker. The primary effectiveness outcome was
the response rate based on a hierarchical clinical compos-
ite score including (a) death, (b) heart failure-related
hospitalization, (c) New-York Heart Association (NYHA)
functional classification, and (d) quality of life using the
EQ-5D questionnaire. Responders’ rate were 76 % in the
SonR arm versus 62 % in the control arm (p = 0.03) at 1
year; this result was driven by improvement of symptoms
[5]. A post-hoc analysis of the study showed that system-
atic optimization (n = 66, three times during one year,
whether the method used SonR or echo) was associated
with more responders as per the clinical composite score,
fewer deaths or heart failure hospitalizations, and fewer
symptoms versus non-systematic optimization (n = 133,
48 % of patients never optimized, 29 % optimized
once, 23 % optimized twice), suggesting that favorable
outcomes were associated with optimization frequency,
not with the optimization method used [6]. A recent cost-
effectiveness analysis found that this repeated optimization
strategy was more cost-effective than the non-systematic
optimization arm in most European countries [7]. Finally,
Duncker at al. published a prospective, multicenter,
non-randomized study designed to assess the safety
and electrical performances of the atrial SonRtip lead
in 99 patients implanted with a CRT device with a
defibrillator (CRT-D) [8].
We describe a case report of a non-responding patient
implanted with this atrial lead, who then responded to
CRT after activation of the sensor.
Case presentation
A 78-year-old Caucasian man presented with dilated is-
chemic cardiomyopathy, left bundle branch block, a left
ventricular ejection fraction (LVEF) of 35 %, NYHA III/
IV heart failure, diabetes, paroxysmal atrial fibrillation
(AF), dyspnea when undergoing mild exercise, and
edema of his lower limbs.
In December 2012, our patient was implanted with a
triple chamber CRT-D device (Paradym RF SonR CRT
9770, Sorin CRM SAS, Clamart, France) and the atrial
lead positioned in the lateral wall (560 Ω, 4.5 mV, 0.50 V
at 0.35 ms). The right ventricular lead was a single coil
implanted in the septum (659 Ω, 15.2 mV, 0.75 V at 0.35
ms) and a bipolar LV lead was inserted through the pos-
terior vein (955 Ω, 0.75 V at 0.35 ms). Because of a re-
currence of AF, the automatic optimization was set off at
discharge. Consequently, the device recorded the
hemodynamic SonR signal, but did not optimize AV and
VV delays. Nominal AV and VV delays were pro-
grammed at hospital discharge (125 ms for AV and 0 ms
for VV). Our patient’s anti-arrhythmic treatment con-
sisted of amiodarone, 200 mg daily. While his QRS
width was 195 ms before implant; it decreased down to
120 ms just after implantation. Echocardiography also
showed a left ventricular end diastolic volume (LVEDV)
of 135 mL and left ventricular end systolic volume
(LVESV) of 85 mL.
Five months after implant (in May 2013), our patient’s
clinical status remained impaired, with a LVEF of 30 %,
NYHA III/IV, QRS width of 96 ms, slight mitral regurgi-
tation, LVEDV of 134 mL, and LVESV of 93 mL. The
SonR signal amplitude had also decreased from 0.52 g to
0.29 g (Fig. 1). Nevertheless, because our patient no lon-
ger presented with AF (only one 6-day mode switch
episode recorded shortly after implant), the anti-
arrhythmic treatment was stopped and the SonR
optimization system was activated.
After 2 months of automatic CRT-D optimization
(7 months after implantation), our patient’s clinical
status had significantly improved (LVEF of 60 %,
NYHA II, no mitral regurgitation, optimal ventricular
filing [E/A timing] with AV optimization, stable QRS
width, LVEDV of 104 mL, and LVESV of 42 mL). His
symptoms (dyspnea and lower limb edema) had dis-
appeared at the 7-month post-implant visit. Opti-
mized by the device, AV and VV delays at 85 ms and
R+L 16 ms, respectively, were confirmed to be opti-
mal both by echo and EA filling time. In addition,
the SonR signal amplitude doubled shortly after the
first weekly automatic optimization (Fig. 1).
The different echocardiographies of our patient were
performed by the same operator.
Discussion
CRT optimization could not initially be performed in
our patient because of paroxysmal AF. Once the AF
ceased, weekly AV and VV delay optimizations were
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automatically activated using a hemodynamic device-
based sensor. Symptoms and ventricular function (LVEF,
mitral regurgitation, ventricular filing) were significantly
improved after 2 months of CRT optimization.
Significant clinical improvements after AV and VV
optimization have previously been reported in two
studies evaluating device-based optimization algorithms
[5, 9]. The multicenter, single-blind, randomized (1:1)
CLEAR trial compared CRT-P optimized using SonR
and CRT optimized according to the centers’ usual prac-
tices, mostly by echocardiography. One-year results
showed an improvement of symptoms (NYHA func-
tional class) in 83 % of patients versus in 64 % of pa-
tients treated with CRT alone (p = 0.002). The evolution
of QRS duration, LVESD, and LVEF was similar in both
arms from baseline to 1 year [5].
In a recent paper by Oliveira et al., 17 patients im-
planted with the SonRtip atrial lead and CRT-D de-
vice showed a significant increase in LVEF, with a
76.5 % rate of reverse remodeling, defined as an im-
provement of at least one NYHA functional class and
a decrease >15 % of their LVESV at 6 months com-
pared with baseline [10].
These pilot studies and preliminary results warrant an
evaluation of the device in a controlled randomized trial.
The double-blinded, multicenter, non-inferiority RE-
SPOND- CRT trial will assess the clinical effectiveness and
reverse remodeling of systematic automatic optimization
versus a single echocardiographic optimization after
implantation [11].
In this case report, QRS did not appear to be an index
for CRT response, because it remained stable through-
out the follow-up.
Conclusions
Device-based automatic AV and VV delay CRT optimization
significantly improved symptoms and ventricular function in
a non-responding patient after 2 months.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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Fig. 1 SonR parameters (interventricular delay at rest, sensed atrioventricular delay at rest, and SonR signal amplitude) before and after activation
of the automatic optimization (in May 2013) and echocardiography
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